Related Experiment Video
Updated: Feb 16, 2026

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
A Lipidomics Approach to Identifying Key Lipid Species Involved in VEGF-Inhibitor Mediated Attenuation of
Yogesh M Kulkarni1, Sucharita Dutta2, Anand Krishnan V Iyer1
1Department of Pharmaceutical Sciences, School of Pharmacy, Hampton University, Hampton, VA, USA.
Purpose:
Poor molecular characterization of idiopathic pulmonary fibrosis (IPF) has led to insufficient understanding of the pathogenesis of the disease, resulting in lack of effective therapies and poor prognosis. Particularly, the role of lipid imbalance due to impaired lipid metabolism in the pathogenesis of IPF has been poorly studied.
Experimental Design:
The authors have used shotgun lipidomics in a bleomycin (BLM) mouse model of pulmonary fibrosis with vascular endothelial growth factor (VEGF)-inhibitor CBO-P11 as a therapeutic measure, to identify a comprehensive set of lipids that contribute to the pathogenesis of pulmonary fibrosis.
Results:
The authors report that attenuation of BLM-induced fibrotic response with CBO-P11 cotreatment is accompanied by a decrease in total lipid content and specific downregulation of lipids, which are upregulated in response to BLM treatment.
Conclusion And Clinical Relevance:
Dysregulated lipids identified in this study hold the potential of being future biomarkers for IPF.
Insights
Idiopathic pulmonary fibrosis (IPF) research reveals that lipid metabolism is key. Targeting lipid imbalance with CBO-P11 in a mouse model reduced fibrosis, suggesting new therapeutic avenues for IPF.
Area of Science:
- Pulmonary Medicine
- Lipidomics
- Pathogenesis Research
Background:
- Idiopathic pulmonary fibrosis (IPF) lacks effective therapies due to poor molecular understanding.
- Impaired lipid metabolism and resulting lipid imbalance are understudied contributors to IPF pathogenesis.
Purpose of the Study:
- To identify specific lipids involved in pulmonary fibrosis pathogenesis.
- To investigate the therapeutic potential of targeting lipid metabolism in IPF.
Main Methods:
- Utilized shotgun lipidomics in a bleomycin (BLM)-induced mouse model of pulmonary fibrosis.
- Administered vascular endothelial growth factor (VEGF)-inhibitor CBO-P11 as a therapeutic intervention.
Main Results:
- CBO-P11 treatment attenuated BLM-induced fibrotic responses.
- Therapeutic intervention led to decreased total lipid content.
- Specific lipids upregulated by BLM were downregulated with CBO-P11 cotreatment.
Conclusions:
- Dysregulated lipids identified in this study are potential future biomarkers for IPF.
- Targeting lipid metabolism presents a promising therapeutic strategy for IPF.
More Related Videos
Related Concept Videos
Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
What is a Species?
Keystone Species
Structure of Lipids
Formation of Species

